Paradigm Capital Management Inc. NY Sells 100,000 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Paradigm Capital Management Inc. NY decreased its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 33.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 200,000 shares of the company’s stock after selling 100,000 shares during the quarter. Paradigm Capital Management Inc. NY owned 0.77% of Eton Pharmaceuticals worth $2,664,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in Eton Pharmaceuticals in the fourth quarter valued at about $86,000. Jefferies Financial Group Inc. acquired a new stake in Eton Pharmaceuticals during the fourth quarter valued at approximately $133,000. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Eton Pharmaceuticals by 18.3% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock valued at $141,000 after purchasing an additional 1,634 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $147,000. Finally, Bank of America Corp DE raised its holdings in shares of Eton Pharmaceuticals by 5,422.4% in the 4th quarter. Bank of America Corp DE now owns 11,100 shares of the company’s stock worth $148,000 after buying an additional 10,899 shares in the last quarter. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Trading Up 3.4%

NASDAQ ETON opened at $19.57 on Tuesday. The firm has a market cap of $524.83 million, a price-to-earnings ratio of -88.95 and a beta of 1.22. The company has a 50 day moving average of $14.91 and a 200-day moving average of $14.04. Eton Pharmaceuticals, Inc. has a 1-year low of $3.18 and a 1-year high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $17.28 million for the quarter, compared to the consensus estimate of $14.33 million. On average, analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Analysts Set New Price Targets

ETON has been the topic of several recent analyst reports. B. Riley reaffirmed a “buy” rating and issued a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Finally, Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.